mCRC-话题@MedSci

#mCRC#

38篇内容 | 2150人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1642752, encodeId=5a0c1642e52f0, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益, objectType=article, longId=186925, objectId=3f7618692587, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f7618692587, replyNumber=0, likeNumber=123, createdTime=2021-01-07, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f7618692587, moduleTitle=PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f7618692587)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642750, encodeId=632a1642e5023, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=【2019 ASCO】化疗难治性mCRC患者瑞戈非尼治疗新进展, objectType=article, longId=167648, objectId=f57f16e64875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f57f16e64875, replyNumber=0, likeNumber=87, createdTime=2019-08-06, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f57f16e64875, moduleTitle=【2019 ASCO】化疗难治性mCRC患者瑞戈非尼治疗新进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f57f16e64875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642751, encodeId=74531642e51da, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗, objectType=article, longId=175233, objectId=c5631e5233ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5631e5233ba, replyNumber=0, likeNumber=150, createdTime=2019-11-10, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5631e5233ba, moduleTitle=BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5631e5233ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642747, encodeId=189c1642e47cd, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=J Clin Oncol:CheckMate 142研究：dMMR/MSI-H 型mCRC的联合免疫治疗时代, objectType=article, longId=127483, objectId=749e12e48327, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=749e12e48327, replyNumber=0, likeNumber=72, createdTime=2018-09-26, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=749e12e48327, moduleTitle=J Clin Oncol:CheckMate 142研究：dMMR/MSI-H 型mCRC的联合免疫治疗时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=749e12e48327)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642748, encodeId=c0721642e4823, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=JAMA Surg：mCRC的靶向治疗：肿瘤原发部位和死亡率是否相关？, objectType=article, longId=131399, objectId=622d13139946, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=622d13139946, replyNumber=0, likeNumber=103, createdTime=2018-11-16, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=622d13139946, moduleTitle=JAMA Surg：mCRC的靶向治疗：肿瘤原发部位和死亡率是否相关？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=622d13139946)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642749, encodeId=56611642e49d5, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=JCO：贝伐珠单抗治疗mCRC 18q11.2-q12.1缺失是福还是祸？, objectType=article, longId=146653, objectId=33e41466537f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33e41466537f, replyNumber=0, likeNumber=86, createdTime=2019-04-08, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33e41466537f, moduleTitle=JCO：贝伐珠单抗治疗mCRC 18q11.2-q12.1缺失是福还是祸？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33e41466537f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642742, encodeId=2cd11642e42bf, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=合理制定靶向药物使用顺序，使mCRC患者获益很大化, objectType=article, longId=106021, objectId=c9b710602185, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9b710602185, replyNumber=0, likeNumber=73, createdTime=2017-12-10, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9b710602185, moduleTitle=合理制定靶向药物使用顺序，使mCRC患者获益很大化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9b710602185)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642744, encodeId=fb351642e445e, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=ANN ONCOL:液体活检RAS可指导mCRC一线抗EGFR治疗, objectType=article, longId=108461, objectId=a9e21084618a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9e21084618a, replyNumber=0, likeNumber=63, createdTime=2017-11-15, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9e21084618a, moduleTitle=ANN ONCOL:液体活检RAS可指导mCRC一线抗EGFR治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9e21084618a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642741, encodeId=cc511642e41da, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=Ann Oncol：血液和肿瘤组织的RAS突变检测方法用于指导mCRC抗EGFR治疗的一致性, objectType=article, longId=105800, objectId=603c10580098, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=603c10580098, replyNumber=0, likeNumber=81, createdTime=2017-08-18, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=603c10580098, moduleTitle=Ann Oncol：血液和肿瘤组织的RAS突变检测方法用于指导mCRC抗EGFR治疗的一致性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=603c10580098)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642746, encodeId=8dc21642e46e9, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=J Clin OncoL:BRAF突变mCRC再细分，新突变亚型引人瞩目, objectType=article, longId=108813, objectId=a8b410881330, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8b410881330, replyNumber=0, likeNumber=106, createdTime=2018-07-14, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8b410881330, moduleTitle=J Clin OncoL:BRAF突变mCRC再细分，新突变亚型引人瞩目, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8b410881330)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642745, encodeId=c73d1642e4505, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=ANNALS OF ONCOLOGY：液体活检RAS可指导mCRC一线抗EGFR治疗, objectType=article, longId=108462, objectId=42e5108462d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42e5108462d0, replyNumber=0, likeNumber=83, createdTime=2018-04-15, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42e5108462d0, moduleTitle=ANNALS OF ONCOLOGY：液体活检RAS可指导mCRC一线抗EGFR治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42e5108462d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642743, encodeId=d3441642e435c, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=【ASCO 2017】欧美权威专家访谈集锦：Her-2扩增检测为mCRC末线治疗方案提供线索, objectType=article, longId=106341, objectId=64261063415a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64261063415a, replyNumber=0, likeNumber=92, createdTime=2018-06-19, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64261063415a, moduleTitle=【ASCO 2017】欧美权威专家访谈集锦：Her-2扩增检测为mCRC末线治疗方案提供线索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64261063415a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642740, encodeId=60d21642e40da, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=Ann Oncol：血浆ctDNA RAS基因突变分析用于mCRC患者诊断和治疗监测效果佳, objectType=article, longId=105262, objectId=a60610526214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a60610526214, replyNumber=0, likeNumber=94, createdTime=2018-03-14, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a60610526214, moduleTitle=Ann Oncol：血浆ctDNA RAS基因突变分析用于mCRC患者诊断和治疗监测效果佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a60610526214)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642738, encodeId=cc211642e3856, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者, objectType=article, longId=43695, objectId=811c4369574, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=811c4369574, replyNumber=0, likeNumber=94, createdTime=2015-04-18, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=811c4369574, moduleTitle=RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=811c4369574)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642739, encodeId=1df61642e392a, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=ASCO 2015：化疗后卡培他滨单药维持对mCRC的疗效, objectType=article, longId=51425, objectId=80e15142500, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80e15142500, replyNumber=0, likeNumber=62, createdTime=2015-12-19, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80e15142500, moduleTitle=ASCO 2015：化疗后卡培他滨单药维持对mCRC的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80e15142500)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642737, encodeId=da4d1642e3714, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=CSCO 2014：徐瑞华:晚期mCRC患者标准治疗失败后的新选择值得期待, objectType=article, longId=40492, objectId=8caf404928a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8caf404928a, replyNumber=0, likeNumber=91, createdTime=2014-12-26, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8caf404928a, moduleTitle=CSCO 2014：徐瑞华:晚期mCRC患者标准治疗失败后的新选择值得期待, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8caf404928a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642735, encodeId=40f81642e35ef, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=ASCO 2014专家点评：mCRC一线靶向治疗抗VEGF还是抗EGFR？, objectType=article, longId=35106, objectId=224f351069b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=224f351069b, replyNumber=0, likeNumber=83, createdTime=2014-09-13, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=224f351069b, moduleTitle=ASCO 2014专家点评：mCRC一线靶向治疗抗VEGF还是抗EGFR？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=224f351069b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642736, encodeId=bf471642e368e, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=S-1/奥沙利铂 (SOX)联合贝伐珠单抗与5-FU/l-LV/奥沙利铂(mFOLFOX6)联合贝伐珠单抗治疗转移性结直肠癌(mCRC)(SOFT研究), objectType=article, longId=37048, objectId=c4a63e048dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4a63e048dd, replyNumber=0, likeNumber=89, createdTime=2014-10-18, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4a63e048dd, moduleTitle=S-1/奥沙利铂 (SOX)联合贝伐珠单抗与5-FU/l-LV/奥沙利铂(mFOLFOX6)联合贝伐珠单抗治疗转移性结直肠癌(mCRC)(SOFT研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4a63e048dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642734, encodeId=421d1642e3417, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果, objectType=article, longId=34270, objectId=a77a342e036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a77a342e036, replyNumber=0, likeNumber=76, createdTime=2014-11-10, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a77a342e036, moduleTitle=CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a77a342e036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642733, encodeId=6b421642e3316, content=<a href='/topic/show?id=b70711396cd' target=_blank style='color:#2F92EE;'>#mCRC#</a>, objectTitle=CHMP建议批准拜耳regorafenib用于转移性结直肠癌(mCRC)治疗, objectType=article, longId=20869, objectId=d9a32086951, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9a32086951, replyNumber=0, likeNumber=99, createdTime=2013-10-26, rootId=0, userName=LShY0906_98743851, userId=8c9723008141, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9a32086951, moduleTitle=CHMP建议批准拜耳regorafenib用于转移性结直肠癌(mCRC)治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9a32086951)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mCRC

2020-05-29

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

PLK1抑制剂Onvasertib治疗KRAS突变的mCRC患者：肿瘤消退和临床获益

2021-01-07

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

【2019 ASCO】化疗难治性mCRC患者瑞戈非尼治疗新进展

2019-08-06

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

BRAF、EGFR、MEK，三靶向无化疗方案或成为BRAF V600E突变型mCRC新标准治疗

2019-11-10

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

J Clin Oncol:CheckMate 142研究：dMMR/MSI-H 型mCRC的联合免疫治疗时代

2018-09-26

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

JAMA Surg：mCRC的靶向治疗：肿瘤原发部位和死亡率是否相关？

2018-11-16

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

JCO：贝伐珠单抗治疗mCRC 18q11.2-q12.1缺失是福还是祸？

2019-04-08

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

合理制定靶向药物使用顺序，使mCRC患者获益很大化

2017-12-10

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

ANN ONCOL:液体活检RAS可指导mCRC一线抗EGFR治疗

2017-11-15

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

Ann Oncol：血液和肿瘤组织的RAS突变检测方法用于指导mCRC抗EGFR治疗的一致性

2017-08-18

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

J Clin OncoL:BRAF突变mCRC再细分，新突变亚型引人瞩目

2018-07-14

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

ANNALS OF ONCOLOGY：液体活检RAS可指导mCRC一线抗EGFR治疗

2018-04-15

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

【ASCO 2017】欧美权威专家访谈集锦：Her-2扩增检测为mCRC末线治疗方案提供线索

2018-06-19

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

Ann Oncol：血浆ctDNA RAS基因突变分析用于mCRC患者诊断和治疗监测效果佳

2018-03-14

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

RECOURSE试验III期：TAS-102对比安慰剂治疗已给予更佳支持治疗且能耐受标准化疗的mCRC患者

2015-04-18

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

ASCO 2015：化疗后卡培他滨单药维持对mCRC的疗效

2015-12-19

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

CSCO 2014：徐瑞华:晚期mCRC患者标准治疗失败后的新选择值得期待

2014-12-26

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

ASCO 2014专家点评：mCRC一线靶向治疗抗VEGF还是抗EGFR？

2014-09-13

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

S-1/奥沙利铂 (SOX)联合贝伐珠单抗与5-FU/l-LV/奥沙利铂(mFOLFOX6)联合贝伐珠单抗治疗转移性结直肠癌(mCRC)(SOFT研究)

2014-10-18

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

CPP：MET过表达预测KRAS野生型mCRC患者抗EGFR疗法效果

2014-11-10

LShY0906_98743851 (审核中...)

前往app查看评论内容

#mCRC#

CHMP建议批准拜耳regorafenib用于转移性结直肠癌(mCRC)治疗

2013-10-26

科室
- - 订阅+
  - 更多科室
工具
服务